1. Gaziano TA. Cardiovascular diseases worldwide. In: Public Health Approach to Cardiovascular Disease Prevention & Management. Boca Raton: CRC Press, 2022; 8-18.
2.
Abou Bakr M, Gebreil A, Shaker AM. ST-segment elevation myocardial infarction. Cardiovasc Coronary Artery Imaging 2022; 2: 13-33.
3.
Šarenac D. Myocardial revascularization – where do we stand through the guidelines window. Cardiol Cardiovasc Res 2024; 2: 1-9.
4.
Khaled S, Jaha N, Shalaby G. Clinical characteristics and short-term outcomes of patients presenting with acute myocardial infarction having multi-vessel disease – a single middle-eastern tertiary-care center experience. Indian Heart J 2022; 74: 28-33.
5.
Mignatti A, Echarte-Morales J, Sturla M, et al. State of the art of primary PCI: present and future. J Clin Med 2025; 14: 653.
6.
Ghani A, Dambrink JH, Van ‘T Hof AW, et al. Treatment of non-culprit lesions detected during primary PCI: long-term follow-up of a randomised clinical trial. Neth Heart J 2012; 20: 347-53.
7.
Engstrøm T, Kelbæk H, Helqvist S, et al. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3 – PRIMULTI): an open-label, randomised controlled trial. Lancet 2015; 386: 665-71.
8.
Smits PC, Abdel-Wahab M, Neumann FJ, et al. Fractional flow reserve-guided multivessel angioplasty in myocardial infarction. N Engl J Med 2017; 376: 1234-44.
9.
Mehta SR, Wood DA, Storey RF, et al. Complete revascularization with multivessel PCI for myocardial infarction. N Engl J Med 2019; 381: 1411-21.
10.
Members WC, Lawton JS, Tamis-Holland JE, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2022; 79: e21-129.
11.
Ruiz-Garcia J, Lerman A, Weisz G, et al. Age- and gender-related changes in plaque composition in patients with acute coronary syndrome: the PROSPECT study. EuroIntervention 2012; 8: 929-38.
12.
Zanchin C, Ledwoch S, Bär S, et al. Acute coronary syndromes in young patients: phenotypes, causes and clinical outcomes following percutaneous coronary interventions. Int J Cardiol 2022; 350: 1-8.
13.
Aslanabadi N, Mashayekhi S, Rezvani M, et al. A comparison between culprit versus complete revascularization in diabetic patients with acute myocardial infarction. Clin Cardiol 2024; 47: e70046.
14.
Zhao Z, Witzenbichler B, Mintz GS, et al. Dynamic nature of nonculprit coronary artery lesion morphology in STEMI: a serial IVUS analysis from the HORIZONS-AMI trial. JACC Cardiovasc Imaging 2013; 6: 86-95.
15.
Yalcinkaya R, Öz FN, Durmuş SY, et al. Is there a role for laboratory parameters in predicting coronary artery involvement in Kawasaki disease? Klin Padiatr 2022; 234: 382-7.
16.
Hong MK, Mintz GS, Lee CW, et al. Comparison of coronary plaque rupture between stable angina and acute myocardial infarction: a three-vessel intravascular ultrasound study in 235 patients. Circulation 2004; 110: 928-33.
17.
Stone GW, Maehara A, Lansky AJ, et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med 2011; 364: 226-35.
18.
Lee PH, Huang SM, Tsai YC, et al. Biomarkers in contrast-induced nephropathy: advances in early detection, risk assessment, and prevention strategies. Int J Mol Sci 2025; 26: 2869.
19.
Narayanan MA, Reddy YN, Sundaram V, et al. What is the optimal approach to a non-culprit stenosis after ST-elevation myocardial infarction – conservative therapy or upfront revascularization? An updated meta-analysis of randomized trials. Int J Cardiol 2016; 216: 18-24.
20.
Yalcinkaya A, Öztaş YE, Sabuncuoğlu S. Sterols in inflammatory diseases: implications and clinical utility. Adv Exp Med Biol 2023: 261-75.
21.
Bhatt DL. Do we really know the CvLPRIT in Myocardial infarction? or just stent all lesions? J Am Coll Cardiol 2015; 65: 973-5.
22.
O’gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 61: e78-140.
23.
Wald DS, Morris JK, Wald NJ, et al. Randomized trial of preventive angioplasty in myocardial infarction. N Engl J Med 2013; 369: 1115-23.
24.
Gershlick AH, Khan JN, Kelly DJ, et al. Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CvLPRIT trial. J Am Coll Cardiol 2015; 65: 963-72.
25.
Di Mario C, Mara S, Flavio A, et al. Single vs multivessel treatment during primary angioplasty: results of the multicentre randomised HEpacoat for cuLPrit or multivessel stenting for Acute Myocardial Infarction (HELP AMI) Study. Int J Cardiovasc Intervent 2004; 6: 128-33.
26.
Politi L, Sgura F, Rossi R, et al. A randomised trial of target-vessel versus multi-vessel revascularisation in ST-elevation myocardial infarction: major adverse cardiac events during long-term follow-up. Heart 2010; 96: 662-7.
27.
Atti V, Gwon Y, Narayanan MA, et al. Multivessel versus culprit-only revascularization in STEMI and multivessel coronary artery disease: meta-analysis of randomized trials. JACC Cardiovasc Interv 2020; 13: 1571-82.
28.
Tian J, Ren X, Vergallo R, et al. Distinct morphological features of ruptured culprit plaque for acute coronary events compared to those with silent rupture and thin-cap fibroatheroma: a combined optical coherence tomography and intravascular ultrasound study. J Am Coll Cardiol 2014; 63: 2209-16.
29.
Kozomara N, Tešić M, Jevtović M, editors. Significance and Prognostic Value of Non-culprit Intermediate Stenosis in Patients Early After Primary Percutaneous Coronary Intervention. International Conference of Experimental and Numerical Investigations and New Technologies. CNNTech, 2024; 171-179.
30.
Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2019; 40: 87-165.
